Crowdfunding campaign reaches 48% of target in just two weeks!

BelluscuraNews

After just two weeks of our @Crowdcube campaign, we are already at 48% of our funding target! We are excited to have brought on 73 investors from 9 countries. 16 days remaining in the campaign, so don’t miss out on this unique healthcare investment opportunity! Investment Notice: Neither Belluscura or Crowdcube is soliciting investors in the United States, Canada or … Read More

David Poutney, CEO of Dowgate Capital, is supporting Belluscura’s Crowdfunding initiative

BelluscuraNews

“Belluscura’s patented technology in the medical oxygen space has huge commercial potential whilst at the same time providing significant benefits to the lives of those suffering from COPD. I lost a dear friend to this debilitating disease and X-PLOR would have made a tremendous difference to quality of life in his final years. With other important applications in other fields … Read More

Second week of Crowdcube campaign

BelluscuraNews

In just one week, our crowdfunding campaign @ Crowdcube brought on 51 investors from 6 countries. 23 days left in the campaign so be sure to take advantage of this healthcare investment opportunity!     Investment Notice: Neither Belluscura or Crowdcube is soliciting investors in the United States, Canada or Japan or any other country where it would be unlawful … Read More

Nigel Wray, serial investor, owner of Saracens Rugby Club and 25% shareholder, is supporting Belluscura’s Crowdfunding initiative

BelluscuraNews

“I invest in many small companies and I am extremely excited about Belluscura’s X-PLOR oxygen concentrator, and the benefit it will have on COPD sufferers. That is why I am backing this business.”                Investment Notice: Neither Belluscura or Crowdcube is soliciting investors in the United States, Canada or Japan or any other country … Read More

Belluscura Launches Crowdfunding Campaign

BelluscuraNews

Our Crowdfunding Campaign is Live on Crowdcube! Take a look at this unique opportunity for investors in the UK and other countries where permitted. Investment Notice: Belluscura is not soliciting investors in the United States, Canada or Japan. You must be resident in the United Kingdom or a country where you may legally receive financial promotions of the nature provided … Read More

Belluscura expands its oxygen therapy technology with the filing of a broad patent application covering oxygen enrichment inventions relating to a portable artificial lung and wound care devices

BelluscuraNews

LONDON, UK AND PLANO, TX  Belluscura PLC, in conjunction with its exclusive research partner Separation Design Group, announced today the recent filing of a broad patent application. The latest patent application, titled “Improved Extracorporeal Membrane Oxygenation Device, System and Related Methods,” involves incorporating and expanding their existing oxygen enrichment patent portfolio into an innovative, next generation portable artificial lung and a … Read More

Belluscura Expands its Patent Portfolio Covering Respiratory, Postoperative Recovery and Artificial Intelligence

BelluscuraNews

Belluscura plc, improving healthcare through innovation, in conjunction with its exclusive research partner Separation Design Group, announced today the recent filing of three patent applications and the notice of allowance of a fourth application in the fields of respiratory, postoperative recovery, sedation/sleep monitoring and artificial intelligence. The latest patent application, titled “System and method for improving patient recovery postoperatively,” involves … Read More

Belluscura PLC Closes Out Latest Private Placement Funding Round of $1.935M

BelluscuraNews

Belluscura plc has raised US$1.935M in a private placing with a further US$346,000 coming in the form of loan conversions. The placing was priced at US$0.18 (£0.13) per share, giving Belluscura a post-money valuation of approximately US$4.3M. Established in 2015, Belluscura has so far launched three products with two more in development. The money raised will be used to further … Read More

Belluscura plc to Present at 2018 UK Investor Show and Mello 2018

BelluscuraNews

Belluscura plc (“Belluscura”) will be attending and presenting at the 2018 UK Investor Show (www.ukinvestorshow.com) on April 21, 2018 at the Queen Elizabeth II Conference Centre in London, UK. On April 26 and 27 Belluscura will be attending and presenting at Mello 2018 (www.mello2018.com) at the Derby Conference Centre in Derby, UK. Regarding both investor conferences, Bob Rauker, CEO of … Read More

Belluscura Ltd Raises US$1.3M and Converts $0.268m in Loans to Equity in Latest Financing Round

BelluscuraNews

Belluscura Ltd. (“Belluscura”) has concluded a private placement to raise approximately US$1.33m (the “Private Placement”) through Dowgate Capital Stockbrokers and converted loans equal to approximately US$268k to equity under the same terms as the Private Placement. This Private Placement was priced at US$0.18 (13p) per share, giving Belluscura a post-money valuation of approximately US$3.7m. Belluscura will extend the Private Placement … Read More